Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

Highlights

A comprehensive analysis of over 1 million patients diagnosed with cancer during the first two years of the COVID-19 pandemic reveals a troubling shift in oncology outcomes. Key findings include:

• Significant absolute reductions in 1-year cause-specific survival (CSS) for both early-stage and late-stage cancer diagnoses in 2020 and 2021.
• An estimated 17,390 excess cancer-related deaths occurred within one year of diagnosis—a 13.1% increase over expected mortality based on prepandemic trends.
• The most pronounced survival drops were observed in elderly populations (aged 65+) and individuals of minoritized racial and ethnic backgrounds.
• Site-specific analyses highlighted substantial survival declines in early-stage esophageal and colorectal cancers, as well as late-stage prostate cancer.